✦ LIBER ✦

1098 ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE HAS A FAVORABLE SAFETY PROFILE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL-BASED CHEMOTHERAPY: RESULTS FROM COU-AA-301, A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PHASE III STUDY

✍ Scribed by Fizazi, K.; De Bono, J.; Haqq, C.; Logothetis, C.C.; Jones, R.J.; Chi, K.; Kheoh, T.; Molina, A.; Scher, H.

Book ID: 122746720
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 196 KB
Volume: 10
Category: Article
ISSN: 1569-9056
DOI: 10.1016/S1569-9056(11)61076-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

705 ABIRATERONE ACETATE PLUS LOW-DOSE PR

705 ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE HAS A FAVORABLE SAFETY PROFILE, IMPROVES SURVIVAL AND PRODUCES PSA AND RADIOGRAPHIC RESPONSES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL-BASED CHEMOTHERAPY: RESULTS FROM COU-AA-301, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY

✍ Saad, Fred; de Bono, Johann S.; Haqq, Christopher M.; Logothetis, Christopher J. 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 56 KB

127 Improved survival in elderly (≥75 yr

127 Improved survival in elderly (≥75 yr) metastatic castration-resistant prostate cancer (mCRPC) patients upon treatment with abiraterone acetate (AA) plus prednisone (P) progressing after docetaxel-based chemotherapy: Results from COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study

✍ P.F.A. Mulders; A. Molina; M. Marberger; F. Saad; J.H. Li; T. Kheoh; C.M. Haqq; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 37 KB